Sensei Biotherapeutics (SNSE) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Conference overview

• H.C. Wainwright's 26th Annual Global Investment Conference featured over 6,600 companies across sectors such as life sciences, fintech, technology, clean tech, and mining, with events held September 9th-11th, 2024.

• The conference included live and streaming presentations, one-on-one meetings, and panels, providing a platform for corporate updates and industry insights.

Sensei Biotherapeutics presentation highlights

• Focused on conditionally active antibodies, with lead program SNS-101 targeting the immune checkpoint VISTA, currently in phase I-B dose expansion.

• SNS-101 designed for pH-sensitive binding, overcoming previous VISTA antibody challenges like poor PK and cytokine release syndrome (CRS).

• Clinical data show SNS-101 avoids target-mediated drug disposition and severe CRS, with only mild, transient CRS events observed.

• SNS-101 demonstrated tumor accumulation in acidic environments and no binding at physiological pH, supporting its safety and efficacy profile.

• The program targets large, unmet needs in cancers such as non-small cell lung, melanoma, head and neck, and colorectal, with a combined incidence of 2.6 million new patients annually in the US and EU7.

Clinical and financial updates

• Phase I dose escalation completed, with up to 15 mg/kg dosing achieved, far exceeding prior VISTA antibody studies.

• Early efficacy signals include stable disease and tumor regression in difficult-to-treat, PD-1-resistant cancers, including partial responses in MSS endometrial and colon cancers.

• Dose expansion phase is enrolling 50-70 patients with "hot" tumors, focusing on those who failed prior PD-1/PD-L1 therapies.

• Initial data from the dose expansion cohort expected in Q4 2024, with cash runway into Q4 2025 to support ongoing studies and operations.

• Platform includes three additional preclinical candidates, with IND filings planned in the coming quarters or years.